Home / Transcripts / Alamar Biosciences, Inc. (ALMR) · November 3, 2026

Alamar Biosciences, Inc. (ALMR) Earnings Call Transcript

November 3, 2026

NASDAQ US Health Care Life Sciences Tools and Services earnings 52 min

Earnings Call Speaker Segments

Yuling Luo executive
#1

Thanks, Carrie. And thanks to everyone for being with us this afternoon. I'll open the call with a quick overview of Alamar and our platform, then go through the Q3 business highlights and our strategy for capturing the opportunity in front of us. After that, I'll hand things to Justin, who will cover our financials and update the full-year outlook. Beginning on Slide 3. We started Alamar around a bold mission: making it possible to detect disease at the earliest stage through precision proteomics. That purpose continues to steer every choice we make. Proteomics ranks among the biggest opportunities in life science, and much of it is still untapped. Researchers spent years wanting to quantify the proteins that indicate disease, yet the instruments for detecting them well were simply unavailable. Alamar came into being to solve that issue. Turning to Slide 4. Precision proteomics calls for five capabilities operating together: ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation. Under other technologies, scientists have faced trade-offs, giving up sensitivity to obtain multiplexing, or giving up steps to keep the workflow simple. Alamar stands alone as the platform that provides all five without compromise. From the January 2024 launch of our precision proteomics platform, customers have taken it up quickly, and that momentum continued through this quarter. Now let's look at the top line results on Slide 5. For the third quarter, total revenue was up 68% compared with a year earlier, and consumables drove that growth — up 79% and making up 53% of total revenue. Gross margin also continued to improve, hitting 61.5% in Q3 for the first time. With that performance, we're raising our full-year revenue guidance. Moving to Slide 6: our near-term growth strategy has 3 drivers. First, expanding the installed base into new institutions and geographies. Second, building new content — both to deepen our position in neurology and inflammation, where we first established the platform, and to move into adjacent disease areas with significant unmet need. Third, we're collaborating with top-tier institutions and biopharma companies on fresh applications and sizable studies, and that has expanded our publication record while fueling awareness and uptake. If you'll turn to Slide 7, we're continuing to achieve meaningful progress throughout our business. There's growing evidence that NULISA is the preferred platform for accessing the low-abundance proteome, and that edge produced two notable wins recently. We were chosen to carry out U.K. Biobank's Vanguard study on blood-based biomarkers for neurodegeneration, profiling 80,000 samples, and we were also chosen for a major partnership with GSK, profiling over 60,000 samples to support its drug discovery program. Our published body of work has expanded past 200 papers and preprints — among them, a study in The Lancet Neurology that represents the first longitudinal assessment of a wide plasma biobank panel among patients on anti-amyloid therapy in real-world settings. We likewise bolstered our Board and leadership ranks. Bob Ragusa, formerly CEO of GRAIL and formerly Chief Operations Officer of Illumina, has joined our Board of Directors. Bob played a key role in building two of the most notable companies in genomics and early cancer detection, and he believes that in the future, disease detection will come through multi-marker testing that uses proteins. As we progress toward clinical applications, his expertise will be extremely valuable. We're also glad to welcome John Brottem, who joins as General Counsel, and Amelia Merrill, who comes aboard as Chief People Officer, as we expand the organization for the next stage of growth. If you'll turn to Slide 8. The data and biological insight our customers keep producing continue to inspire us. During our User Group Meeting in October, customers presented compelling new findings covering treatment response in prostate cancer, healthy aging, and protein quantitative trait loci, or pQTLs, which connect genetic variation with protein levels. A great deal of this work is enabled by our capacity to access the low-abundance proteome. Many of the proteins most critical in disease—cytokines, signaling molecules, and proteins released by the brain, for example—exist in blood at extremely low levels. Conventional approaches often can't pick them up dependably, or can't pick them up whatsoever, and platforms that assay many proteins at once typically boost sensitivity as they scale up; that gap matters most in the applications with the greatest potential impact, including early disease detection, disease risk prediction, and minimal residual disease, where signals are faint and ultra-high sensitivity becomes essential. NULISA was built specifically to address this challenge, quantifying hundreds of low-abundance proteins at the same time from a small blood sample. That's the reason NULISA is being picked more and more by researchers and biopharma partners who need large-scale access to this part of the proteome. And it matters even more as machine learning and AI models trained on proteomic data keep gaining ground in the field. Those models figure out what disease looks like by setting it against health. So they need to see low-abundance proteins accurately measured in healthy samples, where the levels are often at their lowest. When a platform can't detect a protein, that missing value typically gets filled in by statistical methods, and a model trained on data like that may pick up patterns that reflect the measurement gaps rather than real biology. Having reliable detection in both healthy and diseased samples gives these models a more accurate foundation, and we believe that as AI takes on a central role in biomarker discovery, data generated on our platform will become increasingly valuable. Please turn to Slide 9. The U.K. Biobank study is a great illustration of the field recognizing the value of our platform; in October, we were selected alongside Nightingale Health to deliver UK Biobank's Vanguard study, which focuses on blood-based biomarkers for neurodegenerative disease. Conducted on NULISA within Nightingale's laboratories, the study will measure 220 neurologically relevant proteins across 80,000 blood samples from people who were healthy at enrollment. Established by The Michael J. With backing from the Fox Foundation, LifeArc and ARUK, this study is set to create one of the biggest open-access tools worldwide for grasping the earliest molecular indicators of neurodegeneration. Proteins originating in the brain—plus other proteins that exist only in minuscule quantities—will, for the very first time, be measured through UK Biobank, which stands among the most extensively used health research resources anywhere on the planet. This will also bring about the first-ever definitive proteomics data set for Parkinson's disease, the neurological disorder that is outpacing all others in growth and that affects more than 12 million people today. Together with Alzheimer's disease, which touches over 55 million people globally, these conditions are usually diagnosed only once years or decades of molecular damage have already taken place. Analyzing people long before any symptoms appear gives us a chance to catch the earliest signals while intervention is still possible. We expect the study to wrap up by the end of 2027, and the data it produces will be merged with imaging, genetic and longitudinal health information from UK Biobank and opened up to approved researchers worldwide. Turning to Slide 10. Earlier today we announced a strategic scientific partnership with GSK, which represents yet another strong endorsement of our platform from the biopharma sector. Together, we'll examine the ways in which protein signatures found in the bloodstream relate to how disease advances, to biological subtypes, and to how patients respond to treatment across respiratory, liver, kidney, neurological and autoimmune conditions, using real-world health care data that reflects patients much more accurately than clinical trials do. The work will focus on connecting protein signals with clinical outcomes, finding new biomarkers, revealing the biological subtype concealed within a single diagnosis, and comprehending how patients react to therapies that already exist.

Yuling Luo executive
#2

People who carry this diagnosis frequently have disease that differs at the biological level, and that is still among the core difficulties in developing drugs; our view is that NULISA can assist with stratifying patients as early as possible and enhance the way the disease is classified and treated. To back this collaboration, we'll profile over 60,000 serum samples with the NULISAseq Immune 340 Panel and Neuro 220 Panel; through this partnership we'll build one of the most comprehensive biomarker data sets applied to GSK's drug discovery program, and it will let Alamar potentially develop and commercialize novel protein signatures in precision prevention, treatment and earlier disease detection. Moving to Slide 11. Our scientific footprint keeps expanding. During Q3 we brought in more than 35 publications and preprints, pushing our cumulative count past 200 spanning neurodegenerative disease, oncology and autoimmune conditions. Several of these studies demonstrate our latest product in action. Just three months after launch, an initial pre-print employing our eMTBR-Tau assay supports its role in staging Alzheimer's disease. A paper in Nature Medicine likewise supports new uses for our platform in women's health. An independent study out of Emory University, published in Nature Communications, identified a 10-protein signature that distinguishes ALS from healthy controls at 98% balanced accuracy in the validation cohort, compared with approximately 90% for NFL on its own. That plainly shows why measuring multiple proteins simultaneously is important. Each fresh piece of research adds separate proof of NULISA's capabilities and brings additional investigators onto our platform. Turning to Slide 12. What excites us greatly is seeing NULISA yield fresh understanding within a translational context. Research out of Dr. Carlos Cruchaga's lab at Washington University, released in the Lancet Neurology this quarter, offers an excellent example. That work is the first longitudinal effort to assess a wide plasma biomarker panel among patients on anti-amyloid therapy in routine clinical care. Using our NULISAseq CNS 120 Panel, the team quantified 130 proteins across roughly 2,400 samples drawn from lecanemab-treated patients and an untreated comparison group, consuming merely 25 microliter of plasma per sample. The results addressed a major unresolved issue in Alzheimer's treatment. Why is it that removing amyloid doesn't produce comparable clinical gains across all patients? The protein associated with amyloid removal differed substantially from those linked to subsequent cognitive deterioration, indicating that these represent separate biological mechanisms. Within the treated group, 34 out of 130 biomarkers showed meaningful change throughout treatment, and their shifts were not uniformly in one direction. The research further illustrates the importance of sensitivity and specificity. The brain-originating version of tau reliably surpassed the same protein found circulating elsewhere in the body, making up 4 of the 5 leading markers that separate treated patients from controls. Separating brain-derived tau from its periphery form and measuring it along with the more than 100 other proteins from a single, small sample is exactly what our platform was built to do. With more therapies entering routine care and late-stage trials, one or 2 markers aren't sufficient to grasp how patients are responding to treatment. What this study demonstrates is the richer picture that our platform is able to deliver, and it addresses directly what our pharma partners require as they seek to understand treatment response within their own programs. Moving to Slide 13. What we continue to hear from customers—along with the research I just described—makes us more convinced than ever that the future of testing will be driven by multi-marker protein panels. Two patients with the same diagnosis can differ greatly in the biology underneath it; and in complicated conditions like Alzheimer's, scientists and drug makers also need to understand which pathologies are present, where the disease stands in its progression, and how someone is responding to therapy. Those questions cannot all be answered by any one protein. That becomes even more important as testing scales up to entire populations. In broad screening where a disease is fairly uncommon, accuracy that falls short even slightly can mean cases get missed or many people are wrongly flagged as positive. We believe single marker tests will not be sensitive or specific enough for that setting, and that testing which measures many proteins together will become the standard. 20 years ago, the market moved from single marker PCR testing to next-generation sequencing, and that transition transformed oncology and ushered in a new era of precision medicine. We expect a similar shift in proteomics, from single marker immunoassays to multi-marker protein signatures capable of guiding diagnosis, prognosis, treatment selection and disease monitoring across the entire patient journey. NULISA was built to lead that shift. Moving to Slide 14. That shift toward multi-marker testing is what makes the opportunity ahead of us so large. The research market we address today is sizable by itself, with projections putting it at $11 billion within ten years. In our view, the same platform could extend into clinical diagnostics, early detection, and health monitoring across whole populations. Deep multiplexing paired with the sensitivity clinical work demands is what enables that. Our starting strategy is to offer the platform as a foundation for partners. We supply the hardware and the operating system, while a partner bringing disease knowledge, clinical development and regulatory know-how, reimbursement routes, and commercial reach develops the applications—diagnostic tests, in our case. Getting there requires us to finish work on ARGO HT/DX, our clinical instrument, which we intend to file with the FDA for marketing authorization before next year ends. We see this enabling use in late-stage trials, allowing partners to create LDT and IVD tests, and boosting research demand, because customers appreciate a tool whose route to the clinic is clear. Once authorized, we plan to work with IVD and LDT partners to build differentiated tests, offered either standalone or as part of multiomic solutions; proteomics stands at a remarkable juncture today, and in my view Alamar occupies a distinctive position to shape where this field goes next. What this team has created fills me with real pride, and the road ahead gives me great energy. With that, I'll hand the call over to Justin.

Justin McAnear executive
#3

Thanks, Yuling. Good afternoon, everyone. I'm glad to take you through the details of our third quarter 2026 financial results. Except where we say otherwise, every growth rate is a year-over-year comparison. Also, a quick reminder: we intend to refresh the installed base and average instrument pull-through metrics once a year, and we'll share those figures on our year-end 2026 earnings call. Moving to Slide 15. Revenue for the third quarter totaled $33.5 million, a rise of 68% from $19.9 million in the third quarter of 2025. Consumables remained the strongest contributor, making up over half of total revenue in the third quarter. Consumables revenue reached $17.8 million, up 79% year-over-year, on robust demand for our multiplex panel kits. Instrument revenue for the third quarter came in at $8.5 million, up 50%, fueled by continued growth in new instrument placements. We're happy with how placements are progressing, and the installed base keeps supporting a robust, expanding stream of recurring consumables revenue. Service and other revenue was $7.2 million this quarter. As a reminder, this line is mostly TAP services, with maintenance contracts a smaller piece, since a large share of our instrument installed base remains within its initial 1 year warranty. TAP is meant to attract new customers, support custom assay development and beta test new products ahead of launch. I want to pause and recognize our TAP team for delivering our biggest TAP revenue quarter-to-date. A number of sizable custom assay development projects and population studies were finished by the team during the quarter, and that drove the result; we do not anticipate a similar level repeating in Q4. Consequently, TAP revenue is expected to fall sequentially in Q4. Longer term, we continue to anticipate that the remainder of the business will outpace TAP. Turning to Slide 16. Let's now go through the geographic breakdown for the third quarter. Revenue was 70% from the Americas, 20% from EMEA and 10% from APAC; we continue to extend our international footprint, and we see considerable runway in EMEA as well as APAC as we reinforce distribution partnerships and direct commercial efforts across those regions. Turning to how our customers break down: biopharmaceutical firms accounted for 49% of Q3 revenue, while academic and research institutions contributed 44%, and distributors made up the remaining 7%. This is the first quarter where biopharma customers have made up the biggest portion of revenue, rising from 42% in Q2. Studies run by biopharma customers are typically larger and longer in duration, which generates meaningful consumables pull-through as time goes on, and we're encouraged by the growing traction our platform is seeing in drug development. Now to Slide 17. Third quarter gross profit came in at $20.6 million, compared with $11.9 million in the same period last year. Gross margin was 61.5% for the third quarter of 2026, an increase from 59.7% in the third quarter of 2025. Our gross margin reached another record high. A number of items contributed to this gain: lower instrument costs, increased average selling prices for consumables, improved margins on TAP services, and a beneficial shift in product mix. Total operating expenses for the third quarter were $35.8 million, compared with $19.8 million in the same period last year. This increase reflects investments in personnel, infrastructure, and consumable content, as well as added costs associated with being a public company. Research and development expenses for the quarter totaled $16.2 million, a 58% increase from $10.2 million a year earlier. That growth reflects higher lab supply costs supporting our expanding consumable panel menu, along with an increase in personnel costs. Selling, general and administrative expenses were $19.6 million for the quarter, up 105% from $9.6 million in the prior-year period. Higher personnel expenses and increased spending on professional services, including legal and accounting fees, were the primary factors. Operating loss for the third quarter came to $15.1 million, versus $7.9 million in the same period of 2025. Included in that number was $3.9 million in stock-based compensation for Q3 2026, compared with $0.7 million in Q3 2025. The quarter's net loss totaled $13.3 million, against $8 million in Q3 2025; we ended the third quarter on strong financial footing; and at September 30, 2026, our cash, cash equivalents, short-term investments, and restricted cash stood at $231.5 million. Our balance sheet gives us ample funding to carry out our strategy, and we plan to put that money to work in a deliberate way—growing the company and its capabilities to support future expansion. That means adding to our commercial sales and support team, boosting manufacturing capacity, and strengthening R&D so we can broaden product content. If you'll turn to Slide 18, here's how we see the remainder of the year. We're lifting our revenue guidance for all of 2026 and now anticipate a range of $121 million to $123 million, which works out to 64% annual growth at the midpoint. Previously, we had guided to $116 million to $120 million. Looking ahead to Q4, we anticipate that higher consumables revenue will make up for the decline we foresee in TAP. Turning to costs, we expect operating expenses to rise during the fourth quarter as we move forward some R&D initiatives originally slated for 2027. Speeding up this effort underpins our content and instrument road map, and our commitment to a disciplined route toward profitability is unchanged. With that, I'll hand the call back to Yuling.

Yuling Luo executive
#4

Thank you, Justin. Before I turn to our objectives, I want to recognize Todd White. As we shared in today's earlier announcement, Todd plans to retire at the end of this year, and following that he will continue in an advisory role with the company until June 2027. Todd and I have collaborated for more than 25 years. When he joined Alamar in 2021 as our Chief Financial Officer and Chief Business Officer, he carried that same spirit of trust and partnership into the work of building this company. Todd was instrumental in establishing the groundwork for our growth — spanning the finance organization and operations, as well as steering us through our IPO. Speaking for myself, I feel real appreciation for his friendship, the advice he has offered, and all that he has contributed to Alamar. Our Board and the whole team want to say thank you, Todd. A capable leadership group is already in place, and we are in a solid position to continue carrying out our plan. Todd is here with us now and will take part in the Q&A. Before we begin taking your questions, I'd like to revisit the targets we set out three months ago. If you turn to Slide 19, regarding the first and second goals, we are still on schedule to expand our installed base by no fewer than 100 instruments during 2026 and to keep pull-through per instrument above $400,000. Regarding goal three—moving toward larger-scale studies—the partnerships with UK Biobank and GSK represent precisely the sort of advancement we intended. As we look toward 2027, our plans include continuing to grow our installed base, introducing a multiplex panel in an additional disease area, filing ARGO HT/DX for FDA marketing authorization, and forming partnerships that support our diagnostic strategy. I'd like to thank the Alamar team for delivering another strong quarter. We possess the capital, the road map, and the personnel needed to seize the opportunity before us. With that said, we'll now take questions. Operator?

Dan Brennan analyst
#5

Congratulations on the quarter. Perhaps to begin, regarding the near-term momentum in TAP and what that suggests for Q4, I heard Justin and Yuling talk about it and it seems like more of a one-time thing. I'm not sure whether there was any pull forward, but could you discuss a bit why the strength you saw in Q3 won't carry on? I mean, you came off a really strong Q2 as well. And then, related to that, on consumables, the pull-through was better than expected too. Any color you can give on what you're seeing there and what's driving that upside?

Justin McAnear executive
#6

Yes. Thanks for the question, Dan; this is Justin. I'll take that one. When it comes to TAP results for Q3, Q3 benefited from some large custom assay development projects, which we don't expect to repeat at the same level in Q4. TAP projects are typically driven in part by customer time lines. So which quarter they land in can vary. And so when we look at the second half of 2026, we see that playing out in whole, slightly above where we had described it last quarter with some timing shifts into Q3 from Q4. Regarding the pipeline and what we're seeing in consumables, I will say, overall, our pipeline remains strong. Our underlying business remains on track. As far as instruments go, we expect to place 100 or more instruments this year. And as far as consumables go, there are no meaningful changes in trends to call out from what we've experienced before. And we are still tracking to keep pull-through above 400,000 average annual instrument pull-through for the year.

Dan Brennan analyst
#7

Great. And now perhaps regarding the Glaxo and U.K. Biobank deals—could you offer some detail? Both matter significantly on their own, of course, yet how should we view the revenue opportunity? I realize these represent meaningful validation for the platform, but purely from a revenue standpoint, any insight into how that flows into the model across roughly the next 18 months? And whatever you can share about the pipeline for additional large deals that may be in progress?

Yuling Luo executive
#8

I'll take that first, and Justin may add to it. We're delighted to report that NULISA was chosen for the 80,000 sample study. The major opportunity, in my view, lies in where this project takes us. UK Biobank ranks among the most extensively used data sets in biomedical research, and thousands of researchers globally will be working with the NULISA data. This provides the field with a large, high-quality data set demonstrating the worth of measuring low-abundance proteins at population scale. It reinforces our standing in other large cohort studies that we're actively pursuing. Over time, we anticipate that funding from this study will generate demand for follow-up studies, translational work and ultimately clinical applications—all of which run on our platform. Justin?

Justin McAnear executive
#9

On the timing question, Dan, you've got it right — this unfolds across several quarters. With UK Biobank, sample processing should get underway in Q4, and we've factored that into the guidance we just updated, with a ramp expected in 2027. When it comes to disclosing how much revenue any one project contributes specifically, that's not something we'd normally do. That said, as I mentioned, the contributions we anticipate for Q4 were baked into the updated guidance we just provided.

Yuling Luo executive
#10

I'd like to add something to what Justin said — we've just made our collaboration with GSK public. For us, this collaboration is genuinely exciting. It demonstrates that the major pharma companies see worth in platforms that go past neurodegeneration. It's growing into a number of new disease applications, including respiratory, liver, kidney and autoimmune, and it's used in real-world patient samples. It also amounts to strong validation of the value biopharma is finding in our platform.

Puneet Souda analyst
#11

Let's begin with the guidance. You came in roughly $4 million above expectations, and your increase was about the same size. I value the comments you made regarding TAP. Still, even reaching the upper bound of the full-year guide would mean revenue that is flat quarter over quarter. You also have U.K. Biobank arriving, plus conversion from TAP into additional consumables, and Q4 typically brings stronger placements. I can't tell whether a budget flush is part of it as well. Given all of those drivers, could you take us through the reasoning for why it comes out only flat sequentially?

Justin McAnear executive
#12

Yes. Thank you for the question, Puneet; we lifted our full-year guide so that it reflects a robust third quarter. We are being cautious as we look at Q4. As I noted, the step-up happened in the latter half of the year sooner than we had initially anticipated. As we stated, Q3 benefited from a number of sizable custom assay development projects within TAP. We do anticipate that top line will decline from Q3 to Q4. After that, we expect consumables revenue to rise sequentially from Q3 to Q4. And then the high end of the range would represent a sequential gain from Q3 to Q4.

Puneet Souda analyst
#13

Understood. Still, one thing I believe we had hoped to see by now is how many instruments are in the pipeline and might also fall under the TAP program — with some of these customers stepping up more decisively compared with the 100 you laid out for the year, which is a solid figure. I'm simply curious about what feedback you've gotten on instrumentation. Is anything preventing them — whether funding or simply timing? And perhaps you could also walk us through ARGO. ARGO obviously carries a substantial value proposition; so I'm just trying to get a sense of when those instrument placements should begin to rise meaningfully.

Justin McAnear executive
#14

I'll take that first, Puneet, and then Yuling can chime in afterward. That said, I'd describe our instrument pipeline as robust; it's still quite strong. Quarter after quarter across the last several, we've grown the count of placements. We see a number of instruments as potential upside looking ahead over the near-term quarters, and our 2027 instrument funnel is shaping up well. On placement dynamics broadly, for this quarter it split about 50 to 50 between academic and biopharma, broadly tracking our total revenue; the sales cycle runs longer given the cost, though I wouldn't point to any significant shifts versus prior quarters. And we remain genuinely enthusiastic about the opportunity in front of us.

Yuling Luo executive
#15

With that in mind, although the pipeline is still solid and robust, I'd say predicting when replacements happen has become more difficult. Still, on the whole, we definitely observe the installed base continuing to grow.

Dan Arias analyst
#16

Alzheimer's is obviously a foundational therapeutic area for you folks. But you noted that Parkinson's is in fact the quickest-expanding neurological condition, if I'm not mistaken. I'm wondering whether the extent to which biomarker science is keeping up with how often the disease occurs is something you see as a driver for placements down the road and then for project work down the road? How would you stack Parkinson's against Alzheimer's momentum right now? It would just help to have some context on that.

Yuling Luo executive
#17

Yes. So obviously, during the past 2 years, the biggest uptake of our platform has been in the Alzheimer's disease space, where we have distinctive offerings and high-value biomarkers capable of measuring those — for example, pTau217 MTBR markers in blood. And that truly is a differentiation we have built. And now, with the recent launch of Neuro 220, we have broadened our content from covering Alzheimer's disease to Parkinson's as well as other disease areas. And that is why the research community is very enthusiastic about our Neuro 220, and that is one of the key reasons why UK Biobank has chosen us for this large-scale 80,000 sample studies. Keep in mind, we disclosed last quarter, we had a collaboration with Michael J. Fox Foundation, where they funded us to deliver more than a dozen proprietary unique biomarkers for Parkinson's disease. And that really is one of the main reasons we are able to conduct this large-scale study within UK Bio and covering pretty much all the other disease patients in the sample cohort. I also observed that we can expand past the Parkinson to other neurodegenerative disease areas such as ALS with a recent publication coming from Emory University, where they found a disease signature that can accurately diagnose Alzheimer's disease at over 98% accuracy compared with a single marker test. So we are quite excited about the adoption of our platform and our panels in the neurodegenerative disease areas. And certainly, we are seeing the application beyond the neurodegenerative disease with the recent announcement of collaboration with GSK and noted that the highlight of this collaboration really concerns the incorporation of Immune 340 covering other disease areas such as respiratory, liver metabolic disease and autoimmune disease.

Dan Arias analyst
#18

So perhaps only to follow up on that: you brought up clinical applications, and Justin brought up pulling forward some R&D dollars — so does that tie to the diagnostic system you guys are developing? Could you maybe speak to how much that research focus is being brought into the picture versus more panel content for research? Maybe it's both. I'm just sort of wondering where you guys are thinking on the R&D front.

Yuling Luo executive
#19

I think certainly inside our company, the aim is to submit for FDA clearance for our ARGO HT/DX platform by the end of next year. With that submission, a test will go through the process; and what we're aiming for is a test able to demonstrate both our platform's ultra-high sensitivity and the multiplex capabilities; and as you can see, many studies out there highlight a number of different multi-marker signatures that provide differentiated performance compared with a single marker test. And we certainly expect, over time, that some of those signatures could turn into LDT and IVD tests in the coming years.

Justin McAnear executive
#20

Yeah, and to build on that, Dan — regarding the remaining acceleration of R&D projects, we're seeing meaningful growth opportunities ahead and have decided to bring some of them forward at this point. These are multiyear programs that we also anticipate will contribute to revenue growth over the longer term; and on top of that, we're intentionally investing in the commercial organization and the public company infrastructure to support growth too.

Casey Woodring analyst
#21

I just want a quick clarification regarding GSK and that 60,000 sample study — I don't believe I heard a timeline for it. At what point do you expect it will be finished?

Yuling Luo executive
#22

Today we announced this strategic type of collaboration. That study gets underway in Q1 2027. Our Immune 340 and Neuro 220 Panel will be used by us to supply over 60,000 serum samples spanning respiratory, liver, kidney, neurological and autoimmune conditions. Revenue contributions from individual projects or partnerships are not something we break out. On a risk-adjusted basis, these studies are included in our internal forecast. As of today, we aren't giving a timeline for its completion.

Casey Woodring analyst
#23

So I suppose my follow-up on that would be about the 2 studies. How should we think about the number of samples you'll be running each quarter, and how that's spread across, say, the 80,000 sample study from UK Biobank — you're going to finish that by the end of '27. Should we just assume roughly 16,000 samples a quarter, given that you're going to start processing in 4Q? Any sense of the per-quarter contribution from a sample volume standpoint would help us understand.

Justin McAnear executive
#24

That can vary from quarter to quarter. There can also be ramp-up time inside the project for additional analysis. So we aren't providing guidance on projects or samples per quarter here. But when the time comes to guide for the full year, we'll be taking this into account in our full-year guide, and we could potentially share more detail then.

Avantika Dhabaria analyst
#25

Nice work on the quarter. For 4Q gross margins, what's the right way to frame it, particularly if TAP declines and consumables increase? Then I've got one more question after that.

Justin McAnear executive
#26

Sure. I'll handle the gross margin piece. It was a strong quarter on gross margin. Looking at the various factors affecting margin, I'd say nearly all of them moved favorably. Overall, the drivers were reduced instrument costs, a higher average selling price on consumables, better margins from TAP services, and a beneficial product mix shift toward consumables. Regarding TAP services as well, within a quarter you have a fairly fixed base in terms of the team size needed to deliver those projects; and when they exceed targets the way they did in Q3, that can give you a gross margin benefit. So I'd caution against viewing the Q3 margin as a floor. This can keep fluctuating from quarter to quarter, I'd note, and future quarters will also be highly sensitive to product mix. But I'd also add that as consumables scale and keep growing as a share of total revenue, we do expect gross margin to trend upward over time.

Avantika Dhabaria analyst
#27

Turning to the placement pipeline, are these placements showing up within new customers, or is it existing customers buying additional instruments?

Justin McAnear executive
#28

Yes. So in Q3, most placements continue to come from new customers. I'd also note that this quarter-to-date has been our largest for instruments going to existing customers in new labs. So essentially it shows our capacity to expand into new teams and application areas. As I said earlier, instrument placements have been roughly 50 to 50 between academic and biopharma, broadly mirroring our overall revenue split too.

Operator operator
#29

Much appreciated. That brings the Q&A portion to a close. We're grateful you joined us for today's conference. At this point the program has ended. You're welcome to disconnect now.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Alamar Biosciences, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Alamar Biosciences, Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.